Upbeat Trial Results For Cypress Bioscience

Cypress Bioscience Inc. (CYPB) reported that its depression drug Milnacipran significantly reduced fibromyalgia pain in a late stage clinical trial. The stock price leaped $7.92 to close at $16.37.